---
title: "Lineage Cell Therapeutics, Inc. (LCTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LCTX.US.md"
symbol: "LCTX.US"
name: "Lineage Cell Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-14T20:57:03.446Z"
locales:
  - [en](https://longbridge.com/en/quote/LCTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LCTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LCTX.US.md)
---

# Lineage Cell Therapeutics, Inc. (LCTX.US)

## Company Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.lineagecell.com](https://www.lineagecell.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-14T04:30:16.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 264 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 53.24% |  |
| Net Profit YoY | -241.41% |  |
| P/B Ratio | 7.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 347794580.87 |  |
| Revenue | 14556000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -103.36% | E |
| Profit Margin | -436.47% | E |
| Gross Margin | -22.80% | E |
| Revenue YoY | 53.24% | A |
| Net Profit YoY | -241.41% | E |
| Total Assets YoY | -0.56% | D |
| Net Assets YoY | -43.72% | E |
| Cash Flow Margin | 29.78% | C |
| OCF YoY | 53.24% | A |
| Turnover | 0.13 | D |
| Gearing Ratio | 61.50% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lineage Cell Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "53.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-241.41%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "347794580.87",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14556000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-103.36%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-436.47%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-22.80%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "53.24%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-241.41%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.56%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-43.72%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "29.78%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "53.24%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "61.50%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.47 | 393/393 | - | - | - |
| PB | 7.81 | 373/393 | 17.70 | 7.79 | 2.73 |
| PS (TTM) | 23.89 | 214/393 | 36.63 | 27.00 | 21.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-25T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 1 | 14% |
| Hold | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.59 |
| Highest Target | 9.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LCTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LCTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LCTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LCTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**